Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026
Middle meningeal artery lidocaine infusion reduces headache after venous sinus stenting for idiopathic intracranial hypertension.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sequeiros Joel, Abo Kasem Rahim, Becerril-Gaitan Andrea, Terry Fernando, Dietz Nicholas, Rahmani Redi, Abecassis Isaac Josh, Williams Brian J, Mistry Akshitkumar M, Ding Dale
Аннотация
BACKGROUND: Headaches after venous sinus stenting (VSS) for idiopathic intracranial hypertension (IIH) are very common and challenging to manage. We evaluated the safety and efficacy of middle meningeal artery (MMA) lidocaine infusion to mitigate post-VSS cephalalgia.
METHODS: We retrospectively reviewed 50 consecutive patients with medically refractory IIH who underwent VSS at a single institution (February 2024-January 2026). Seven patients received bilateral MMA infusion of 50 mg of 1% lidocaine immediately following stent deployment; 43 patients served as controls. The primary outcome was first-day headache burden (normalized sum of VAS scores). Secondary outcomes included total in-hospital opioid consumption (oral morphine equivalents, OME) and procedural complications.
RESULTS: Baseline characteristics and procedural metrics were comparable between groups. The MMA lidocaine infusion group demonstrated a 52% reduction in median first-day headache burden compared to controls (15.1 vs. 31.0; P = 0.012). Opioid consumption was reduced by 83.2% in the treatment arm (median 2.8 mg vs. 16.7 mg; P = 0.008). No complications related to MMA infusion occurred, and all infused MMAs remained patent. No seizures or other neurological or cardiovascular complications were observed.
CONCLUSION: MMA lidocaine infusion may significantly reduce acute pain burden and opioid requirements following VSS in IIH patients. Prospective trials are warranted to confirm the safety and efficacy of this intervention.
METHODS: We retrospectively reviewed 50 consecutive patients with medically refractory IIH who underwent VSS at a single institution (February 2024-January 2026). Seven patients received bilateral MMA infusion of 50 mg of 1% lidocaine immediately following stent deployment; 43 patients served as controls. The primary outcome was first-day headache burden (normalized sum of VAS scores). Secondary outcomes included total in-hospital opioid consumption (oral morphine equivalents, OME) and procedural complications.
RESULTS: Baseline characteristics and procedural metrics were comparable between groups. The MMA lidocaine infusion group demonstrated a 52% reduction in median first-day headache burden compared to controls (15.1 vs. 31.0; P = 0.012). Opioid consumption was reduced by 83.2% in the treatment arm (median 2.8 mg vs. 16.7 mg; P = 0.008). No complications related to MMA infusion occurred, and all infused MMAs remained patent. No seizures or other neurological or cardiovascular complications were observed.
CONCLUSION: MMA lidocaine infusion may significantly reduce acute pain burden and opioid requirements following VSS in IIH patients. Prospective trials are warranted to confirm the safety and efficacy of this intervention.